MSD will pay Hengrui Pharma $200m upfront, up to $1.77bn in development, regulatory and commercial milestones, and royalties ...

BMS says it is combining AI and machine learning with its researchers’ expertise in drug targets and mechanisms of action, to ...

Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the ...

The drug discovery pact between Charles River Laboratories, Valo Health and Flagship Pioneering is starting to bear fruit. | The drug discovery pact between Charles River Laboratories, Valo Health and ...

Jiangsu Hengrui Pharmaceuticals Co Ltd, a global pharmaceutical company focusing on scientific and technological innovation, announced on March 25 that it has entered into an exclusive license ...

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular ...

Clinical data supporting mechanism of action reinforce potential as a novel cancer treatment ...

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today ...

Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY SHANGHAI, March 25, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai ...

WuXi AppTec (Shanghai, China) has sold off two US/UK businesses in February and March, it revealed in its annual results on ...

(Yicai) March 26 -- Shares of Hengrui Pharmaceuticals rose after the Chinese firm granted US-Canadian pharma giant Merck ...